TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines

References

• Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178 - 87; http://dx.doi.org/10.1056/NEJMoa1101245; PMID: 22150036
   PubMed Web of Science ®Google Scholar
• Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, Lockman L, Giannini S, Deschamps M. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin 2010; 6:407 - 19; http://dx.doi.org/10.4161/hv.6.5.11023; PMID: 20953154
   PubMed Web of Science ®Google Scholar
• El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649 - 58; http://dx.doi.org/10.1086/657087; PMID: 20979455
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937 - 49; http://dx.doi.org/10.1016/j.vaccine.2006.06.005; PMID: 16828940
   PubMed Web of Science ®Google Scholar
• Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 2010; 9:299 - 307; http://dx.doi.org/10.1586/erv.09.163; PMID: 20218858
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5:e15559; http://dx.doi.org/10.1371/journal.pone.0015559; PMID: 21203523
   PubMed Web of Science ®Google Scholar
• López-Macías C. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother 2012; 8:411 - 4; http://dx.doi.org/10.4161/hv.18757; PMID: 22330956
   PubMed Web of Science ®Google Scholar
• Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007; 18:537 - 45; http://dx.doi.org/10.1016/j.copbio.2007.10.013; PMID: 18083549
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al, HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161 - 70; http://dx.doi.org/10.1016/S0140-6736(07)60946-5; PMID: 17602732
   PubMed Web of Science ®Google Scholar
• Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 2008; 4:5 - 12; http://dx.doi.org/10.4161/hv.4.1.5559; PMID: 18438104
   PubMed Web of Science ®Google Scholar
• Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241 - 7; http://dx.doi.org/10.1016/S1521-6616(03)00120-7; PMID: 14499247
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E, Protocol 11 study Investigators. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008; 26:686 - 96; http://dx.doi.org/10.1016/j.vaccine.2007.11.043; PMID: 18164106
   PubMed Web of Science ®Google Scholar
• Jackson EM, Herbst-Kralovetz MM. Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PLoS One 2012; 7:e41529; http://dx.doi.org/10.1371/journal.pone.0041529; PMID: 22855691
   PubMed Web of Science ®Google Scholar
• Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol 2010; 17:1850 - 8; http://dx.doi.org/10.1128/CVI.00230-10; PMID: 20962211
   PubMed Web of Science ®Google Scholar
• Harandi AM, Davies G, Olesen OF. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 2009; 8:293 - 8; http://dx.doi.org/10.1586/14760584.8.3.293; PMID: 19249971
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13:552 - 9; http://dx.doi.org/10.1038/nm1589; PMID: 17479101
   PubMed Web of Science ®Google Scholar
• Knuschke T, Epple M, Westendorf AM. The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization. Hum Vaccin Immunother 2013; 10:10; PMID: 23982325
   PubMed Web of Science ®Google Scholar
• Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci U S A 2011; 108:20695 - 700; http://dx.doi.org/10.1073/pnas.1117715108; PMID: 22143779
   PubMed Web of Science ®Google Scholar
• Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 2012; 1:50 - 63; http://dx.doi.org/10.7774/cevr.2012.1.1.50; PMID: 23596577
   PubMedGoogle Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:Suppl S45 - 53; http://dx.doi.org/10.1038/nm1213; PMID: 15812489
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499 - 511; http://dx.doi.org/10.1038/nri1391; PMID: 15229469
   PubMed Web of Science ®Google Scholar
• Beutler BA. TLRs and innate immunity. Blood 2009; 113:1399 - 407; http://dx.doi.org/10.1182/blood-2008-07-019307; PMID: 18757776
   PubMed Web of Science ®Google Scholar
• Chilton PM, Embry CA, Mitchell TC. Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation. Front Immunol 2012; 3:154; http://dx.doi.org/10.3389/fimmu.2012.00154; PMID: 22707952
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124:849 - 63; http://dx.doi.org/10.1016/j.cell.2006.02.019; PMID: 16497593
   PubMed Web of Science ®Google Scholar
• Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998; 72:1345 - 53; PMID: 9445035
   PubMed Web of Science ®Google Scholar
• Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008; 26:1846 - 54; http://dx.doi.org/10.1016/j.vaccine.2008.01.053; PMID: 18325641
   PubMed Web of Science ®Google Scholar
• Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, Ni Y, Arntzen CJ, Herbst-Kralovetz MM. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 2011; 29:5221 - 31; http://dx.doi.org/10.1016/j.vaccine.2011.05.027; PMID: 21640778
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 2004; 350:896 - 903; http://dx.doi.org/10.1056/NEJMoa030595; PMID: 14985487
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Cox RJ. The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. Hum Vaccin Immunother 2012; 8:689 - 93; http://dx.doi.org/10.4161/hv.19568; PMID: 22495121
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165:4778 - 82; PMID: 11045998
   PubMed Web of Science ®Google Scholar
• Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212 - 8; http://dx.doi.org/10.1086/656364; PMID: 20815703
   PubMed Web of Science ®Google Scholar
• Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002; 76:12335 - 43; http://dx.doi.org/10.1128/JVI.76.23.12335-12343.2002; PMID: 12414974
   PubMed Web of Science ®Google Scholar
• Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine 2007; 25:3773 - 80; http://dx.doi.org/10.1016/j.vaccine.2007.02.010; PMID: 17349723
   PubMed Web of Science ®Google Scholar